Statement re Hermal

15 January 2007

                              STATEMENT RE HERMAL                              

Reckitt Benckiser plc (RB.L) today announced that it is conducting a full
strategic review of all options for the Hermal prescription skincare business
acquired as part of Boots Healthcare International (BHI) in January 2006.
Goldman Sachs has been appointed to advise the Company.

Reckitt Benckiser is seeking an early resolution of all options in order to
cause as little disruption to the business as possible.

Hermal represents approximately 1% of Reckitt Benckiser plc's total net
revenues and operating profits.

For Further Information

Tom Corran Reckitt Benckiser [phone]

Senior Vice President, Investor Relations & Corporate Communications

Fiona Fong Reckitt Benckiser [phone]

Head of Corporate Communications